Back

Prognostic staging system correctly identifies high risk groups in cardiac transthyretin amyloidosis treated with tafamidis

31 August 2024 (15:00 - 15:50)
Organised by: Logo
Congress Presentation Part of: Cardiac amyloidosis: how to stage and score Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Mr Maximilian Mueller

German Heart Centre Berlin, Berlin (Germany)

7 More presentations in this session

Presentation thumbnail
Validation of two simple scores to identify increased risk of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction
Doctor M. Llevadot Sesmilo (Badalona, ES)
Abstract Slides Video
Presentation thumbnail
DPD quantification correlates with ECV and disease severity in patients with ATTR-CM
Doctor R. Rettl (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Prognostic significance of right ventricular dysfunction in patients with TTR amyloidosis
Doctor S. Istratoaie (Cluj Napoca, RO) Professor E. Donal (Rennes, FR)
Abstract Slides Video
Presentation thumbnail
Characterizing the progression of subclinical cardiac amyloidosis through artificial intelligence applied to electrocardiographic images and echocardiograms
Doctor E. Oikonomou (New Haven, US)
Abstract Slides Video
Presentation thumbnail
Improving early mortality risk detection in light-chain cardiac amyloidosis patients with routine echocardiographic indicators and mayo staging
Doctor J. Li (Beijing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiac amyloidosis: how to stage and score

The Event

Event poster

ESC Congress 2024

31 August 2024 15:00 CET
You may be interested in
thumbnail
Congress Presentation
Expansion of NAC staging system to define poor prognosis: advanced cardiac transthyretin amyloidosis.
thumbnail
Congress Presentation
Acoramidis has a beneficial effect compared with placebo on change from baseline in NAC ATTR stage at month 30 in patients with ATTR-CM: results from the ATTRibute-CM study
thumbnail
Congress Presentation
Survival in a contemporary, real-world, matched cohort of patients with transthyretin amyloid cardiomyopathy treated vs not treated with tafamidis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources